Emily Olsen / healthcaredive - The tentative deal comes months after CVS Health reached a proposed settlement in the lawsuit alleging major pharmacy benefit managers are inflating insulin costs.
AI Summary: UnitedHealth/Optum Rx reached a proposed settlement with the FTC over alleged anti-competitive insulin rebate and pricing practices, including terms to resolve claims that rebates harmed competition and patients. The agreement would curb disputed pharmacy benefit manager conduct and could reshape how insulin discounts are negotiated and passed through to consumers.
CVS Caremark settles FTC insulin-pricing lawsuit for $13 billion / 14 days
Thousands of Medicare beneficiaries unexpectedly lose 'free' drug plans / 19 days
Bill would let patient drug spending count toward insurance deductibles / 3 months
340B discounts face reform as profits outpace patient benefit / 3 months
AbbVie sues HHS over 340B patient definition and guidance / 3 months
CMS ends Medicare Part D premium subsidy for drug plans / 14 hrs
D.C. appeals court upholds HHS control in 340B rebate dispute / 5 days
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.